TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of providing informed consent~* American Society Anesthesiologists (ASA) rating I-III~* Subjects age 18-80 capable of providing consent.~* Subjects undergoing electroconvulsive therapy using succinylcholine as the sole neuromuscular blocking agent.~* Subjects who have scored ≥23 on the Mini-Mental State Examination.~Exclusion Criteria:~* Subjects who have had a recent thrombotic event, myocardial infarction or stroke or episode of Congestive Heart Failure (CHF) within less than 3 months.~* Subjects who have had a recent cardiovascular surgery within the last 3 months.~* Subjects with active Gastrointestinal bleeding~* Subjects who have asthma, itching or allergic type reaction following aspirin or other NSAID administration~* Subjects with a known hypersensitivity to ibuprofen~* Subjects with heart failure, bleeding disorders or kidney failure~* Subjects taking aspirin, Angiotensin converting enzyme (ACE) inhibitors, or anticoagulants within one month.~* Subjects with any devices used to treat pain (intrathecal pumps, spinal cord stimulators etc)~* Subjects with a history of fibromyalgia or chronic myositis~* Subjects who are pregnant~* Subjects who do not have a phone~* Subjects who have had previous ECT~* Subjects receiving toradol (Ketorolac)~* Subjects with reported renal disease within less than 3 months.~* Subjects who have had previous electroconvulsive therapy within the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sugar water (Type: PLACEBO_COMPARATOR): 500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
- Ibuprofen (Type: ACTIVE_COMPARATOR): 300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Patients must have histologically confirmed liposarcoma, which is recurrent, metastatic or unresectable~* There is no limit to prior chemotherapy regimens; in addition, patients may have prior radiation~* All patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (\>= 20 mm with conventional techniques or \>= 10mm with spiral CT scan); pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s)~* ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2; patients should have an expected survival of at least 3 months~* Absolute neutrophil count \>= 1,000/ul~* Platelets \>= 75000/ul~* Total bilirubin =\< 2.0 g/dl~* AST(SGOT)/ALT(SGPT) =\< 2.0X institutional upper limit of normal~* Brain metastasis is not an exclusion; however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or radiation therapy~* All prior therapy must have been completed at least 3 weeks prior to the patient's entry on this trial~* No concurrent chemotherapy, radiotherapy, immunotherapy or other investigational agents~* Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~* Ability to understand and willingness to sign a written informed consent document~Exclusion~* Patient has had prior treatment with or is currently taking a protease inhibitor~* Patients enrolled cannot be on the following medications: cisapride, triazolam, midazolam, ergot derivatives, amiodarone, quinidine, dihydropyridine calcium antagonists (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, and nisoldipine), sildenafil, dilantin, rifampin or oral contraceptives~* Uncontrolled intercurrent illness~* Patients must have recovered from any expected toxicities of previous chemotherapy or radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncontrolled epilepsy with at least two seizures a month for three consecutive months.~* Age 18 to 50.~* Clinical semiology or electroencephalogram (EEG) consistent with partial onset epilepsy.~* Refractory to an adequate trial of two or more main-line anti-epileptic drugs.~* Ability to keep a seizure diary.~* Normal brain magnetic resonance imaging (MRI) - 3 Tesla, seizure protocol; with the exception of hippocampal sclerosis~Exclusion Criteria:~* History of severe prematurity or neonatal distress, febrile seizures, moderate or sever traumatic brain injury, stroke, brain tumor, meningitis, encephalitis, neurocutaneous syndromes, or intracranial metal objects.~* Evidence of psychogenic epilepsy.~* History of convulsive status epilepticus.~* History of primary generalized epilepsy in a first degree relative.~* Known serious medical illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- all subjects (Type: EXPERIMENTAL): IVIG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: International Substudy Enigma2 on Postoperative Cognitive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult males and females aged ≥ 45 years, undergoing noncardiac surgery and general anaesthesia that exceeds two hours.~At increased risk of cardiac events, defined as any of:~* history of coronary artery disease (angina, MI, Coronary revascularisation-Coronary Artery Bypass Graft (CABG) and Percutaneous Transluminal Coronary Angiography ( PTCA)-, positive stress testing, angiography/other imaging, Q waves on ECG)~* heart failure~* cerebrovascular disease due to atherothrombotic disease~* aortic or peripheral vascular disease~OR~three or more of the following risk factors: age ≥70 years, history of heart failure, diabetes (medicated), hypertension (medicated), preoperative serum creatinine \>175 mmol/L, cholesterol ≥6.2 mmol/L, history of a transient ischemic attack (TIA),~Exclusion Criteria:~1. Dementia (MMS test≤24)~2. Parkinson Disease~3. Patients taking regularly (\>2 weeks) tricyclic antidepressants or neuroleptics~4. Patients suffering from Alcohol Dependency (WHO CRITERIA )~5. Patients suffering from severe hypoacusis or visual loss or any other reason hindering the CANTAB battery testing process~6. Patients with untreated deficit in Vitamin B6, B12 and folic acid~7. Patients with marked impairment of gas-exchange requiring Fi02\> 0.5 intraoperatively~8. Patients with specific circumstances where N2O is contraindicated (eg. volvulus, pulmonary hypertension, raised intracranial pressure) or the use of supplemental oxygen is planned (eg. colorectal surgery)~9. N2O unavailable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitrous Oxide (Type: ACTIVE_COMPARATOR): Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
- Air/Oxygen (placebo) (Type: PLACEBO_COMPARATOR): Receives a mixture of 70% Air in 30% Oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for pathological gambling~* Meets DSM-IV and SCID criteria for alcohol abuse or dependence~* Medically healthy~Exclusion Criteria:~* History of schizophrenia, schizoaffective disorder, or bipolar disorder~* Current diagnosis of substance abuse or dependence, other than alcohol or nicotine~* Current major depression~* Currently suicidal~* History of non-response to an adequate trial of sertraline, defined as 200 mg per day of sertraline for at least a 4-week period~* Previous treatment with relapse prevention therapy for pathological gambling or alcohol dependence within the 3 months prior to study entry~* Requires treatment with psychotropic medication~* Unwilling to consent to a drug-free period, according to the following: 2 weeks of abstinence from antidepressant drugs, other than fluoxetine, buspirone, lithium, anticonvulsants, barbiturates, opiates, or benzodiazepines; 4 weeks of abstinence from clonazepam; 5 weeks of abstinence from fluoxetine~* Clinically significant disorder, including kidney, pulmonary, cerebral vascular, cardiovascular, gastrointestinal, and endocrine disorders~* Abnormal laboratory tests~* Abnormal electrocardiogram~* Pregnant or breastfeeding~* Unwilling to use an adequate method of contraception for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo and Relapse Prevention (Type: PLACEBO_COMPARATOR): Patients will be treated with Relapse Prevention Therapy plus placebo
- Sertraline and Relapse Prevention (Type: ACTIVE_COMPARATOR): Patients will be treated with Relapse Prevention Therapy plus Sertraline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Oral Diet in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- patient 18 yo or above hospitalized in ICU and ventilated more than 5 days and/or with severe denutrition after 5 days of no food intake in ICU without shock and/or respiratory distress~Exclusion Criteria:~* age under 18 yo, pregnancy,~* protected patients~* moribund patient (life expectancy of 48h or below),~* patient with disorders of swallowing~* tracheostomy~* patient with shock and/or respiratory distress

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intervention (Type: EXPERIMENTAL): Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed glioblastoma multiforme~* Supratentorial location~* At least 30% of the tumor volume has been removed at craniotomy as judged from a pre/perioperative MRI~* Ability to understand the concept of investigational therapy~* Tolerates dexamethasone treatment~* Adequate anti-epileptic medication~* BNCT can be delivered within 6 weeks from the date of brain surgery~* A written informed consent~Exclusion Criteria:~* Age less than 18 or greater than 75~* The tumor infiltrates into the optic chiasm or into the deep parts of the brain prohibiting delivery of an adequate radiation dose with BNCT~* Prior radiation therapy to the brain~* Prior chemotherapy, immunotherapy, or gene therapy~* Karnofsky performance score \<70~* Severe cardiac, liver, or kidney failure~* Severe infection~* A cardiac pace-maker, or a metal implant in the head and neck region that will prohibit MRI examination~* Pregnancy or lactation~* Phenylketonuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Active treatment arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed congenital central hypoventilation syndrome (CCHS)~* female~* greater than or equal to 16 years of age~Exclusion Criteria:~* less than 16 years of age~* male~* pregnant~* poor adherence to medications~* inability to perform pulmonary maneuvers for tests~* contraindications to oral contraceptives~* pulmonary hypertension

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Females with CCHS > 16 years old on desogestrel (Type: EXPERIMENTAL): open label studied on drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage II, III, or IV intermediate-grade non-Hodgkin's lymphoma that has not responded to or has relapsed after a standard primary chemotherapy regimen plus at least 1 standard second-line salvage chemotherapy regimen NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC greater than 2000/mm\^3~* Platelet count greater than 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of cardiovascular conditions that contraindicate high dosages of sodium~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious infection requiring treatment~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agent (e.g., interferon or interleukin-2)~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* At least 4 weeks since prior dexamethasone, prednisone, or other corticosteroids~* No concurrent corticosteroids~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* Prior cytodifferentiation therapy allowed~* No prior antineoplaston therapy~* No concurrent antibiotics, antifungals, or antivirals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Geriatric Home Visit Program to Reduce Post-Hip Fracture Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All post hip fracture patients on the hospital's rehabilitation service being discharged to home .~Exclusion Criteria:~* Patients discharged to nursing homes or rehabilitation facilities.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No intervention (Type: NO_INTERVENTION): Standard of care with no home visit
- Home Visit (Type: EXPERIMENTAL): After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ages 5 to 18 with clinical diagnosis of primary spontaneous pneumothorax (symptoms of chest pain and/or shortness of breath and pneumothorax demonstrated on chest radiograph) and no prior history of pneumothorax~Exclusion Criteria:~* Blunt or penetrating trauma~* Cystic fibrosis~* Pneumonia~* Uncontrolled asthma with hospitalization for exacerbation within previous 30 days~* Congenital cystic adenomatoid malformation or congenital lobar emphysema~* History of previous cardiac or pulmonary surgery

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Primary Surgery Group (Type: ACTIVE_COMPARATOR): Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
- Initial Non-operative management (Type: ACTIVE_COMPARATOR): Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years.~* First metastatic breast cancer relapse after treatment for early stage disease~* A minimum of 10 evaluable lesions in the liver on routine x-ray CT imaging~* Patient prescribed cytotoxic, endocrine or biological therapies~* Patient physically and psychologically fit enough to consider sequential WB-- - DWI imaging alongside their standard disease monitoring~* Written informed consent~Exclusion Criteria:~* Diagnosis of other cancer within the last 5 years, other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia~* Diagnosis of brain metastases.~* Contraindication to magnetic resonance MR imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues